(Q36610248)

15 August 2017

Mitomycin C and Vinorelbine for second-line chemotherapy in NSCLC--a phase II trial (English)

1 reference

15 August 2017

phase II clinical trial

0 references

author name string

A Babiak

1

1 reference

15 August 2017

J Hetzel

2

1 reference

15 August 2017

F Godde

3

1 reference

15 August 2017

H-H König

4

1 reference

15 August 2017

M Pietsch

5

1 reference

15 August 2017

M Hetzel

6

1 reference

15 August 2017

language of work or name

English

0 references

publication date

13 March 2007

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

96

1 reference

15 August 2017

7

1 reference

15 August 2017

1052-1056

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6603683

15 August 2017

0 references

cites work

Targeted therapy against Bcl-2-related proteins in breast cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360135

In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360135

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360135

Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360135

Non-small-cell lung cancer progression after first-line chemotherapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360135

Second-line chemotherapy for non-small-cell lung cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360135

30 September 2017

Cancer statistics, 1998.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360135

Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360135

Mitomycin "C" and vinorelbine as second line chemotherapy for metastatic breast carcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360135

Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360135

Trial of vindesine plus mitomycin in stage-3 non-small cell lung cancer. An active regimen for outpatient treatment

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360135

Comparison of vindesine plus cisplatin or vindesine plus mitomycin in the treatment of advanced non-small cell lung cancer.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360135

Optimal two-stage designs for phase II clinical trials

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360135

Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360135

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360135

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360135

Vinorelbine and mitomycin C in anthracycline-pretreated patients with advanced breast cancer.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360135

Chemotherapy for metastatic non-small cell bronchogenic carcinoma: cyclophosphamide, doxorubicin, and etoposide versus mitomycin and vinblastine (EST 2575, generation IV)

20 September 2018

1 reference

12 December 2020

Randomized comparison of two combination regimens versus minimal chemotherapy in nonsmall-cell lung cancer: a Southeastern Cancer Study Group Trial

1 reference

12 December 2020

Phase III trial with and without lonidamine in non-small cell lung cancer

1 reference

12 December 2020

A Randomized Trial with Mitomycin-C/Ifosfamide Versus Mitomycin-C/Vindesine Versus Cisplatin/Etoposide in Advanced Non-Small-Cell Lung Cancer

1 reference

12 December 2020

Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6603683

1 reference

15 August 2017

1 reference

15 August 2017

PubMed publication ID

17353918

1 reference